Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2020. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details as of April 30, 2020:
- Issued Share Capital: 5,384,789,156 Ordinary Shares of 25 pence each.
- Treasury Shares: 367,705,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 5,017,083,206.
Material Changes
The filing text does not provide comparative data against prior periods to identify material changes in financial metrics or capital structure.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. Its sole purpose is to establish the denominator for shareholder notification calculations under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,017,083,206) for compliance with FCA disclosure thresholds.
- Confirm the number of shares held in Treasury (367,705,950) to understand the difference between issued capital and voting rights.
- Note that this filing does not contain operational or financial performance updates; refer to Form 20-F or quarterly reports for those metrics.